Expert Review of Clinical Pharmacology

Papers
(The H4-Index of Expert Review of Clinical Pharmacology is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Sodium-glucose cotransporter 2 inhibitors in frail, older people with type 2 diabetes and heart failure: do we have enough evidence to confidently support the use?190
Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments173
Personalizing tamoxifen therapy in adjuvant therapy: a brief summary of the ongoing discussion54
Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome43
Why is diagnosis, investigation, and improved management of kidney stone disease important? Non-pharmacological and pharmacological treatments for nephrolithiasis41
Reducing the risk of death – a possible outcome in COPD patients39
Renin angiotensin aldosterone inhibitors in the treatment of proteinuria in children with congenital anomalies of the kidney and urinary tract: more evidence needed36
Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis33
Effects of the augmentation with quetiapine or olanzapine on the metabolism of duloxetine: a retrospective analysis30
Prostate cancer and novel pharmacological treatment options–what’s new for 2022?30
Therapeutic drug monitoring of antiretroviral therapy: current progresses and future directions30
Clinical pharmacology of antiplatelet drugs29
JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review29
What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion28
The pharmacotherapeutics of sarcoidosis27
Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy27
Fetal safety of medications used in treating infertility26
Role of tenecteplase in ischemic stroke after 4.5 hours: an evaluation of the TRACE-III trial26
Broadening access to tenofovir alafenamide for the treatment and prevention of HIV-1 infection25
Amylin analogs for the treatment of obesity without diabetes: present and future25
Clinical efficacy and safety of topical difamilast in the treatment of patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials24
Dostarlimab for the treatment of advanced endometrial cancer23
0.11614084243774